CTMX Q3 2017 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$822M

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$24M+599.0% YoY

Gross Profit

$24M100.0% margin

Operating Income

-$11M-45.7% margin

Net Income

-$10M-42.4% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

+175.9%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$387M

Total Liabilities

$342M

Stockholders' Equity

$45M

Cash & Equivalents

$284M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$24M	$3M	+599.0%
Gross Profit	$24M	$3M	+599.0%
Operating Income	-$11M	-$15M	+26.1%
Net Income	-$10M	-$15M	+30.1%